|
1
|
Webb PM and Jordan SJ: Epidemiology of
epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol.
41:3–14. 2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Chandra A, Pius C, Nabeel M, Nair M,
Vishwanatha JK, Ahmad S and Basha R: Ovarian cancer: Current status
and strategies for improving therapeutic outcomes. Cancer Med.
8:7018–7031. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Sakurai M, Matsumoto K, Gosho M, Sakata A,
Hosokawa Y, Tenjimbayashi Y, Katoh T, Shikama A, Komiya H,
Michikami H, et al: Expression of tissue factor in epithelial
ovarian carcinoma is involved in the development of venous
thromboembolism. Int J Gynecol Cancer. 27:37–43. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Yuan Z, Cao D, Yu M, Zhou H, Zhang Y, Yang
J and Shen K: Importance of standard treatment in prognosis of
patients with ovarian cancer and associated cerebral infarction.
Clin Interv Aging. 15:151–157. 2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Takasaki K, Miyamoto M, Takano M, Soyama
H, Aoyama T, Matsuura H, Iwahashi H, Ishibashi H, Sakamoto T and
Furuya K: Thrombotic events induce the worse prognosis in ovarian
carcinomas and frequently develop in ovarian clear cell carcinoma.
Int J Clin Oncol. 24:1273–1283. 2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Machida H, Matsuo K, Yamagami W, Ebina Y,
Kobayashi Y, Tabata T, Kanauchi M, Nagase S, Enomoto T and Mikami
M: Trends and characteristics of epithelial ovarian cancer in Japan
between 2002 and 2015: A JSGO-JSOG joint study. Gynecol Oncol.
153:589–596. 2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Takano M, Kikuchi Y, Yaegashi N, Kuzuya K,
Ueki M, Tsuda H, Suzuki M, Kigawa J, Takeuchi S, Tsuda H, et al:
Clear cell carcinoma of the ovary: A retrospective multicentre
experience of 254 patients with complete surgical staging. Br J
Cancer. 94:1369–1374. 2006.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Miyamoto M, Takano M, Goto T, Kato M,
Sasaki N, Tsuda H and Furuya K: Clear cell histology as a poor
prognostic factor for advanced epithelial ovarian cancer: A single
institutional case series through central pathologic review. J
Gynecol Oncol. 24:37–43. 2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Takano M, Goto T, Kato M, Sasaki N,
Miyamoto M and Furuya K: Short response duration even in responders
to chemotherapy using conventional cytotoxic agents in recurrent or
refractory clear cell carcinomas of the ovary. Int J Clin Oncol.
18:556–557. 2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Diaz ES, Walts AE, Karlan BY and Walsh CS:
Venous thromboembolism during primary treatment of ovarian clear
cell carcinoma is associated with decreased survival. Gynecol
Oncol. 131:541–545. 2013.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Ye S, Yang J, Cao D, Bai H, Huang H, Wu M,
Chen J, You Y, Lang J and Shen K: Characteristic and prognostic
implication of venous thromboembolism in ovarian clear cell
carcinoma: A 12-year retrospective study. PLoS One.
10(e0121818)2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Dunbar A, Bolton KL, Devlin SM,
Sanchez-Vega F, Gao J, Mones JV, Wills J, Kelly D, Farina M,
Cordner KB, et al: Genomic profiling identifies somatic mutations
predicting thromboembolic risk in patients with solid tumors.
Blood. 137:2103–2113. 2021.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Unruh D and Horbinski C: Beyond
thrombosis: The impact of tissue factor signaling in cancer. J
Hematol Oncol. 13(93)2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Lu WJ, Lin KC, Huang SY, Thomas PA, Wu YH,
Wu HC, Lin KH and Sheu JR: Role of a Janus kinase 2-dependent
signaling pathway in platelet activation. Thromb Res.
133:1088–1096. 2014.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Matsuo K, Hasegawa K, Yoshino K, Murakami
R, Hisamatsu T, Stone RL, Previs RA, Hansen JM, Ikeda Y, Miyara A,
et al: Venous thromboembolism, interleukin-6 and survival outcomes
in patients with advanced ovarian clear cell carcinoma. Eur J
Cancer. 51:1978–1988. 2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Prat J: FIGO Committee on Gynecologic
Oncology. FIGO's staging classification for cancer of the ovary,
fallopian tube, and peritoneum: Abridged republication. J Gynecol
Oncol. 26:87–89. 2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Zhou Q, Zhu C, Shen Z, Zhang T, Li M, Zhu
J, Qin J, Xie Y, Zhang W, Chen R, et al: Incidence and potential
predictors of thromboembolic events in epithelial ovarian carcinoma
patients during perioperative period. Eur J Surg Oncol. 46:855–861.
2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Kawaguchi R, Furukawa N and Kobayashi H:
Cut-off value of D-dimer for prediction of deep venous thrombosis
before treatment in ovarian cancer. J Gynecol Oncol. 23:98–102.
2012.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Tasaka N, Minaguchi T, Hosokawa Y, Takao
W, Itagaki H, Nishida K, Akiyama A, Shikama A, Ochi H and Satoh T:
Prevalence of venous thromboembolism at pretreatment screening and
associated risk factors in 2086 patients with gynecological cancer.
J Obstet Gynaecol Res. 46:765–773. 2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Habu Y, Mitsuhashi A, Hanawa S, Usui H,
Horikoshi T, Uno T and Shozu M: High prevalence of pulmonary
embolism prior to cancer therapies in patients with ovarian and
endometrial cancers detected by contrast-enhanced CT using D-dimer
as an index. J Surg Oncol. 124:106–114. 2021.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Hada T, Miyamoto M, Ishibashi H, Matsuura
H, Sakamoto T, Kakimoto S, Iwahashi H, Tsuda H and Takano M:
Survival and biomarker analysis for ovarian mucinous carcinoma
according to invasive patterns: Retrospective analysis and review
literature. J Ovarian Res. 14(33)2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Matsuura Y, Robertson G, Marsden DE, Kim
SN, Gebski V and Hacker NF: Thromboembolic complications in
patients with clear cell carcinoma of the ovary. Gynecol Oncol.
104:406–410. 2007.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Gallego A, Ramon-Patino J, Brenes J,
Mendiola M, Berjon A, Casado G, Castelo B, Espinosa E, Hernandez A,
Hardisson D, et al: Bevacizumab in recurrent ovarian cancer: Could
it be particularly effective in patients with clear cell carcinoma?
Clin Transl Oncol. 23:536–542. 2021.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Hisada Y and Mackman N: Tissue factor and
cancer: Regulation, tumor growth, and metastasis. Semin Thromb
Hemost. 45:385–395. 2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Shinohara A, Kutsukake M, Takahashi M, Kyo
S, Tachikawa E and Tamura K: Protease-activated receptor-stimulated
interleukin-6 expression in endometriosis-like lesions in an
experimental mouse model of endometriosis. J Pharmacol Sci.
119:40–51. 2012.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Huang B, Lang X and Li X: The role of
IL-6/JAK2/STAT3 signaling pathway in cancers. Front Oncol.
12(1023177)2022.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Hu R, Han Q and Zhang J: STAT3: A key
signaling molecule for converting cold to hot tumors. Cancer Lett.
489:29–40. 2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
de Bono JS, Concin N, Hong DS,
Thistlethwaite FC, Machiels JP, Arkenau HT, Plummer R, Jones RH,
Nielsen D, Windfeld K, et al: Tisotumab vedotin in patients with
advanced or metastatic solid tumours (InnovaTV 201): A
first-in-human, multicentre, phase 1-2 trial. Lancet Oncol.
20:383–393. 2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Blank S, Mahdi H, Tehrani O, Ghamande S,
Jain S, Nicacio L, Soumaoro I, O'Malley DM and Innova TV: 882TiP
InnovaTV 208: New weekly dosing cohort in the phase II study of
tisotumab vedotin in platinum-resistant ovarian cancer. Ann Oncol.
31(S646)2020.
|
|
31
|
Guo Y, Nemeth J, O'Brien C, Susa M, Liu X,
Zhang Z, Choy E, Mankin H, Hornicek F and Duan Z: Effects of
siltuximab on the IL-6-induced signaling pathway in ovarian cancer.
Clin Cancer Res. 16:5759–5769. 2010.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Yousefi H, Momeny M, Ghaffari SH,
Parsanejad N, Poursheikhani A, Javadikooshesh S, Zarrinrad G,
Esmaeili F, Alishahi Z, Sabourinejad Z, et al: IL-6/IL-6R pathway
is a therapeutic target in chemoresistant ovarian cancer. Tumori.
105:84–91. 2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Yunianto I, Currie M, Chitcholtan K and
Sykes P: Potential drug repurposing of ruxolitinib to inhibit the
JAK/STAT pathway for the treatment of patients with epithelial
ovarian cancer. J Obstet Gynaecol Res. 49:2563–2574.
2023.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Landen CN, Buckanovich RJ, Sill M, Mannel
RS, Walker JL, Disilvestro P, Mathews CA, Mutch G, Hernandez M,
Martin LP, et al: A phase I/II study of ruxolitinib with frontline
neoadjuvant and post-surgical therapy in patients with advanced
epithelial ovarian, fallopian tube, or primary peritoneal cancer. J
Clin Oncol. 40(5501)2022.
|
|
35
|
Wield AM, Walsh CS, Rimel BJ, Cass I,
Karlan BY and Li AJ: Aspirin use correlates with survival in women
with clear cell ovarian cancer. Gynecol Oncol Rep. 25:78–81.
2016.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Verdoodt FC, Dehlendorff C, Friis S and
Kjaer SK: Non-aspirin NSAID use and ovarian cancer mortality.
Gynecol Oncol. 150:331–337. 2018.PubMed/NCBI View Article : Google Scholar
|
